Chinese consensus on the early screening and surveillance for pancreatic cancer in high-risk individuals (2021, Nanjing)

Pancreatic Disease Collaborative Group, Chinese Society of Digestive Endoscopy

doi:10.3969/j.issn.1001-5256.2022.05.008

Volume 38 Issue 5

May 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(5): 1016-1022

PDF( 3080 KB)

Chinese consensus on the early screening and surveillance for pancreatic cancer in high-risk individuals (2021, Nanjing)

DOI: 10.3969/j.issn.1001-5256.2022.05.008

Pancreatic Disease Collaborative Group, Chinese Society of Digestive Endoscopy

Received Date: 2022-03-10
Accepted Date: 2022-03-12
Published Date: 2022-05-20

Abstract

Abstract

Pancreatic cancer is highly malignant with a low five-year survival rate, which is caused by the difficulties in early diagnosis. At present, there is still no standardized procedure for the early screening for pancreatic cancer in China. With reference to related research advances in China and globally, this consensus proposes 26 recommendations concerning the objective of early screening for pancreatic cancer, high-risk population, initial screening age, follow-up interval, screening items, and timing of operation, which finally forms Chinese consensus on the early screening and surveillance for pancreatic cancer in high-risk individuals.
- Pancreatic Neoplasms,
- Pancreatitis, Chronic,
- Population Surveillance,
- Screening,
- Consensus

ZOU Xiaoping, zouxp@nju.edu.cn; LINGHU Enqiang, linghuenqiang@vip.sina.com

FullText(HTML)

References(123)

References

[1]	SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654.
[2]	CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[3]	YACHIDA S, JONES S, BOZIC I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer[J]. Nature, 2010, 467(7319): 1114-1117. DOI: 10.1038/nature09515.
[4]	MIZRAHI JD, SURANA R, VALLE JW, et al. Pancreatic cancer[J]. Lancet, 2020, 395(10242): 2008-2020. DOI: 10.1016/S0140-6736(20)30974-0.
[5]	OVERBEEK KA, LEVINK I, KOOPMANN B, et al. Long term yield of pancreatic cancer surveillance in high risk individuals[J]. Gut, 2021, DOI: 10.1136/gutjnl-2020-323611. [Online ahead of print]
[6]	VASEN H, IBRAHIM I, PONCE CG, et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: Outcome of long-term prospective follow-up studies from three European expert centers[J]. J Clin Oncol, 2016, 34(17): 2010-2019. DOI: 10.1200/JCO.2015.64.0730.
[7]	CANTO MI, ALMARIO JA, SCHULICK RD, et al. Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance[J]. Gastroenterology, 2018, 155(3): 740-751.e2. DOI: 10.1053/j.gastro.2018.05.035.
[8]	BASTURK O, HONG SM, WOOD LD, et al. A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas[J]. Am J Surg Pathol, 2015, 39(12): 1730-1741. DOI: 10.1097/PAS.0000000000000533.
[9]	ROBERTS NJ, NORRIS AL, PETERSEN GM, et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer[J]. Cancer Discov, 2016, 6(2): 166-175. DOI: 10.1158/2159-8290.CD-15-0402.
[10]	MATTHAEI H, HONG SM, MAYO SC, et al. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer[J]. Ann Surg Oncol, 2011, 18(12): 3493-3499. DOI: 10.1245/s10434-011-1745-9.
[11]	ANDEA A, SARKAR F, ADSAY VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma[J]. Mod Pathol, 2003, 16(10): 996-1006. DOI: 10.1097/01.MP.0000087422.24733.62.
[12]	OWENS DK, DAVIDSON KW, KRIST AH, et al. Screening for pancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement[J]. JAMA, 2019, 322(5): 438-444. DOI: 10.1001/jama.2019.10232.
[13]	GOGGINS M, OVERBEEK KA, BRAND R, et al. Management of patients with increased risk for familial pancreatic cancer: Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium[J]. Gut, 2020, 69(1): 7-17. DOI: 10.1136/gutjnl-2019-319352.
[14]	CHARI ST, LEIBSON CL, RABE KG, et al. Probability of pancreatic cancer following diabetes: a population-based study [J]. Gastroenterology, 2005, 129(2): 504-511. DOI: 10.1016/j. gastro.2005.05.007.
[15]	GALLO M, ADINOLFI V, MORVIDUCCI L, et al. Early prediction of pancreatic cancer from new-onset diabetes: An Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper[J]. ESMO Open, 2021, 6(3): 100155. DOI: 10.1016/j.esmoop.2021.100155.
[16]	STORZ P. Acinar cell plasticity and development of pancreatic ductal adenocarcinoma[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(5): 296-304. DOI: 10.1038/nrgastro.2017.12.
[17]	HOWES N, LERCH MM, GREENHALF W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe[J]. Clin Gastroenterol Hepatol, 2004, 2(3): 252-261. DOI: 10.1016/s1542-3565(04)00013-8.
[18]	SINGHI AD, KOAY EJ, CHARI ST, et al. Early detection of pancreatic cancer: Opportunities and challenges[J]. Gastroenterology, 2019, 156(7): 2024-2040. DOI: 10.1053/j.gastro.2019.01.259.
[19]	MATSUBARA S, TADA M, AKAHANE M, et al. Incidental pancreatic cysts found by magnetic resonance imaging and their relationship with pancreatic cancer[J]. Pancreas, 2012, 41(8): 1241-1246. DOI: 10.1097/MPA.0b013e31824f5970.
[20]	TADA M, KAWABE T, ARIZUMI M, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients[J]. Clin Gastroenterol Hepatol, 2006, 4(10): 1265-1270. DOI: 10.1016/j.cgh.2006.07.013.
[21]	PORUK KE, FIRPO MA, ADLER DG, et al. Screening for pancreatic cancer: why, how, and who?[J]. Ann Surg, 2013, 257(1): 17-26. DOI: 10.1097/SLA.0b013e31825ffbfb.
[22]	ASLANIAN HR, LEE JH, CANTO MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review[J]. Gastroenterology, 2020, 159(1): 358-362. DOI: 10.1053/j.gastro.2020.03.088.
[23]	ANTWI SO, FAGAN SE, CHAFFEE KG, et al. Risk of different cancers among first-degree relatives of pancreatic cancer patients: influence of probands′ susceptibility gene mutation status[J]. J Natl Cancer Inst, 2019, 111(3): 264-271. DOI: 10.1093/jnci/djx272.
[24]	BRUNE KA, LAU B, PALMISANO E, et al. Importance of age of onset in pancreatic cancer kindreds[J]. J Natl Cancer Inst, 2010, 102(2): 119-126. DOI: 10.1093/jnci/djp466.
[25]	HEARLE N, SCHUMACHER V, MENKO FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome[J]. Clin Cancer Res, 2006, 12(10): 3209-3215. DOI: 10.1158/1078-0432.CCR-06-0083.
[26]	DAVEE T, CORONEL E, PAPAFRAGKAKIS C, et al. Pancreatic cancer screening in high-risk individuals with germline genetic mutations[J]. Gastrointest Endosc, 2018, 87(6): 1443-1450. DOI: 10.1016/j.gie.2017.12.019.
[27]	DUDLEY B, BRAND RE. Pancreatic cancer surveillance: who, when, and how[J]. Curr Treat Options Gastroenterol, 2019, 17(4): 681-691. DOI: 10.1007/s11938-019-00247-0.
[28]	VERNA EC, HWANG C, STEVENS PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics[J]. Clin Cancer Res, 2010, 16(20): 5028-5037. DOI: 10.1158/1078-0432.CCR-09-3209.
[29]	KASTRINOS F, MUKHERJEE B, TAYOB N, et al. Risk of pancreatic cancer in families with Lynch syndrome[J]. JAMA, 2009, 302(16): 1790-1795. DOI: 10.1001/jama.2009.1529.
[30]	HU C, HART SN, POLLEY EC, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer[J]. JAMA, 2018, 319(23): 2401-2409. DOI: 10.1001/jama.2018.6228.
[31]	THOMPSON D, EASTON DF. Cancer incidence in BRCA1 mutation carriers[J]. J Natl Cancer Inst, 2002, 94(18): 1358-1365. DOI: 10.1093/jnci/94.18.1358.
[32]	Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers[J]. J Natl Cancer Inst, 1999, 91(15): 1310-1316. DOI: 10.1093/jnci/91.15.1310.
[33]	YANG X, LESLIE G, DOROSZUK A, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families[J]. J Clin Oncol, 2020, 38(7): 674-685. DOI: 10.1200/JCO.19.01907.
[34]	HSU FC, ROBERTS NJ, CHILDS E, et al. Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene [J]. JAMA Oncol, 2021, 7(11): 1664-1668. DOI: 10.1001/ jamaoncol.2021.3701.
[35]	GIARDIELLO FM, OFFERHAUS GJ, LEE DH, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis[J]. Gut, 1993, 34(10): 1394-1396. DOI: 10.1136/ gut.34.10.1394.
[36]	PANNALA R, LEIRNESS JB, BAMLET WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus[J]. Gastroenterology, 2008, 134(4): 981-987. DOI: 10.1053/j.gastro.2008.01.039.
[37]	MAITRA A, SHARMA A, BRAND RE, et al. A prospective study to establish a new-onset diabetes cohort: from the consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer[J]. Pancreas, 2018, 47(10): 1244-1248. DOI: 10.1097/ MPA.0000000000001169.
[38]	PANNALA R, BASU A, PETERSEN GM, et al. New-onset diabetes: A potential clue to the early diagnosis of pancreatic cancer[J]. Lancet Oncol, 2009, 10(1): 88-95. DOI: 10.1016/ S14702045(08)703371.
[39]	SHARMA A, KANDLAKUNTA H, NAGPAL S, et al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes[J]. Gastroenterology, 2018, 155(3): 730-739.e3. DOI: 10.1053/j.gastro.2018.05.023.
[40]	CHEN W, BUTLER RK, LUSTIGOVA E, et al. Validation of the enriching new onset diabetes for pancreatic cancer model in a diverse and integrated healthcare setting[J]. Dig Dis Sci, 2021, 66(1): 78-87. DOI: 10.1007/s10620-020-06139-z.
[41]	SHAH I, WADHWA V, BILAL M, et al. Prospective assessment for prediabetes and new onset diabetes in high risk individuals undergoing pancreatic cancer screening[J]. Gastroenterology, 2021, 161(5): 1689-1691.e1. DOI: 10.1053/j. gastro.2021.06.055.
[42]	MATSUBAYASHI H, MAEDA A, KANEMOTO H, et al. Risk factors of familial pancreatic cancer in Japan: Current smoking and recent onset of diabetes[J]. Pancreas, 2011, 40(6): 974-978. DOI: 10.1097/MPA.0b013e3182156e1b.
[43]	SINGH VK, YADAV D, GARG PK. Diagnosis and management of chronic pancreatitis: A review[J]. JAMA, 2019, 322(24): 2422-2434. DOI: 10.1001/jama.2019.19411.
[44]	WANG LW, LI ZS, LI SD, et al. Prevalence and clinical features of chronic pancreatitis in China: A retrospective multicenter analysis over 10 years[J]. Pancreas, 2009, 38(3): 248-254. DOI: 10.1097/MPA.0b013e31818f6ac1.
[45]	HAO L, PAN J, WANG D, et al. Risk factors and nomogram for pancreatic pseudocysts in chronic pancreatitis: A cohort of 1998 patients[J]. J Gastroenterol Hepatol, 2017, 32(7): 1403-1411. DOI: 10.1111/jgh.13748.
[46]	LOWENFELS AB, MAISONNEUVE P, CAVALLINI G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group[J]. N Engl J Med, 1993, 328(20): 1433-1437. DOI: 10.1056/NEJM199305203282001.
[47]	HAO L, ZENG XP, XIN L, et al. Incidence of and risk factors for pancreatic cancer in chronic pancreatitis: A cohort of 1656 patients[J]. Dig Liver Dis, 2017, 49(11): 1249-1256. DOI: 10.1016/j.dld.2017.07.001.
[48]	RU N, WU SY, WANG L, et al. SPINK1 mutations and risk of pancreatic cancer in a Chinese cohort[J]. Pancreatology, 2021, 21(5): 848-853. DOI: 10.1016/j.pan.2021.05.304.
[49]	COTÉ GA, YADAV D, SLIVKA A, et al. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis[J]. Clin Gastroenterol Hepatol, 2011, 9(3): 266-273; quiz e27. DOI: 10.1016/j.cgh.2010.10.015.
[50]	JOERGENSEN M, BRUSGAARD K, CRVGER DG, et al. Incidence, prevalence, etiology, and prognosis of first time chronic pancreatitis in young patients: A nationwide cohort study[J]. Dig Dis Sci, 2010, 55(10): 2988-2998. DOI: 10.1007/ s10620-009-1118-4.
[51]	REBOURS V, BOUTRON RUAULT MC, SCHNEE M, et al. The natural history of hereditary pancreatitis: a national series[J]. Gut, 2009, 58(1): 97-103. DOI: 10.1136/gut.2008.149179.
[52]	SUN XT, HU LH, XIA T, et al. Clinical features and endoscopic treatment of Chinese patients with hereditary pancreatitis[J]. Pancreas, 2015, 44(1): 59-63. DOI: 10.1097/MPA.0000000000000198.
[53]	WANG ZK, LI W. Progress in the diagnosis and treatment of hereditary pancreatitis[J]. Chin J Gastroenterol Hepatol, 2019, 28(6): 711-713. DOI: 10.3969/j. issn.1006-5709.2019.06.026. 王子恺, 李闻. 遗传性胰腺炎诊治进展[J]. 胃肠病学和肝病学杂志, 2019, 28(6): 711-713. DOI: 10.3969/j. issn.1006-5709.2019.06.026.
[54]	RU N, XU XN, CAO Y, et al. The impacts of genetic and environmental factors on the progression of chronic pancreatitis[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.08.033. [Online ahead of print]
[55]	ROSENDAHL J, WITT H, SZMOLA R, et al. Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis[J]. Nat Genet, 2008, 40(1): 78-82. DOI: 10.1038/ng.2007.44.
[56]	COHN JA, FRIEDMAN KJ, NOONE PG, et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis[J]. N Engl J Med, 1998, 339(10): 653-658. DOI: 10.1056/NEJM199809033391002.
[57]	PFVTZER RH, WHITCOMB DC. SPINK1 mutations are associated with multiple phenotypes[J]. Pancreatology, 2001, 1(5): 457-460. DOI: 10.1159/000055847.
[58]	FJELD K, WEISS FU, LASHER D, et al. A recombined allele of the lipase gene CEL and its pseudogene CELP confers susceptibility to chronic pancreatitis[J]. Nat Genet, 2015, 47(5): 518-522. DOI: 10.1038/ng.3249.
[59]	ZOU WB, BOULLING A, MASAMUNE A, et al. No association between CELHYB hybrid allele and chronic pancreatitis in Asian populations[J]. Gastroenterology, 2016, 150(7): 1558-1560.e5. DOI: 10.1053/j.gastro.2016.02.071.
[60]	WU H, ZHOU DZ, BERKI D, et al. No significant enrichment of rare functionally defective CPA1 variants in a large Chinese idiopathic chronic pancreatitis cohort[J]. Hum Mutat, 2017, 38(8): 959-963. DOI: 10.1002/humu.23254.
[61]	CAZACU IM, FARKAS N, GARAMI A, et al. Pancreatitis associated genes and pancreatic cancer risk: a systematic review and meta analysis[J]. Pancreas, 2018, 47(9): 1078-1086. DOI: 10.1097/MPA.0000000000001145.
[62]	SHINDO K, YU J, SUENAGA M, et al. Lack of association between the pancreatitis risk allele CELHYB and pancreatic cancer [J]. Oncotarget, 2017, 8(31): 50824-50831. DOI: 10.18632/ oncotarget.15137.
[63]	MELLA JM, GÓMEZ EJ, OMODEO M, et al. Prevalence of incidental clinically relevant pancreatic cysts at diagnosis based on current guidelines[J]. Gastroenterol Hepatol, 2018, 41(5): 293-301. DOI: 10.1016/j.gastrohep.2017.12.005.
[64]	STARK A, DONAHUE TR, REBER HA, et al. Pancreatic cyst disease: a review[J]. JAMA, 2016, 315(17): 1882-1893. DOI: 10.1001/jama.2016.4690.
[65]	TANAKA M, FERNÁNDEZ-DEL CASTILLO C, ADSAY V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas[J]. Pancreatology, 2012, 12(3): 183-197. DOI: 10.1016/j.pan.2012.04.004.
[66]	van HUIJGEVOORT N, DEL CHIARO M, WOLFGANG CL, et al. Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(11): 676-689. DOI: 10.1038/s41575-019-0195-x.
[67]	VEGE SS, ZIRING B, JAIN R, et al. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts[J]. Gastroenterology, 2015, 148(4): 819-822; quize12-13. DOI: 10.1053/j.gastro.2015.01.015.
[68]	TANAKA M, FERNÁEZ DEL CASTILLO C, KAMISAWA T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas[J]. Pancreatology, 2017, 17(5): 738-753. DOI: 10.1016/j.pan.2017.07.007.
[69]	The European Study Group on Cystic Tumours of the Pancreas. European evidence based guidelines on pancreatic cystic neoplasms[J]. Gut, 2018, 67(5): 789-804. DOI: 10.1136/ gutjnl-2018-316027.
[70]	Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Associati. Guidelines for the management of pancreatic cystic lesions(2015)[J]. J Clin Hepatol, 2015, 31(9): 1375-1378. DOI: 10.3969/j.issn.1001-5256.2015.09.003. 中华医学会外科学分会胰腺外科学组. 胰腺囊性疾病诊治指南(2015版)[J]. 临床肝胆病杂志, 2015, 31(9): 1375-1378. DOI: 10.3969/j.issn.1001-5256.2015.09.003.
[71]	LOWERY MA, WONG W, JORDAN EJ, et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms[J]. J Natl Cancer Inst, 2018, 110(10): 1067-1074. DOI: 10.1093/jnci/djy024.
[72]	GREENHALF W, LÁVY P, GRESS T, et al. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club[J]. Pancreatology, 2020, 20(5): 910-918. DOI:10.1016/j. pan.2020.05.011.
[73]	MIDHA S, SREENIVAS V, KABRA M, et al. Genetically determined chronic pancreatitis but not alcoholic pancreatitis is a strong risk factor for pancreatic cancer[J]. Pancreas, 2016, 45(10): 1478-1484. DOI: 10.1097/MPA.0000000000000684.
[74]	VUJASINOVIC M, DUGIC A, MAISONNEUVE P, et al. Risk of developing pancreatic cancer in patients with chronic pancreatitis[J]. J Clin Med, 2020, 9(11): 3720. DOI: 10.3390/jcm9113720.
[75]	LOWENFELS AB, MAISONNEUVE P, WHITCOMB DC, et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis[J]. JAMA, 2001, 286(2): 169-170. DOI: 10.1001/jama.286.2.169.
[76]	FARRELL JJ. Prevalence, diagnosis and management of pancreatic cystic neoplasms: Current status and future directions[J]. Gut Liver, 2015, 9(5): 571-589. DOI: 10.5009/gnl15063.
[77]	WEINBERG BM, SPIEGEL BM, TOMLINSON JS, et al. Asymptomatic pancreatic cystic neoplasms: maximizing survival and quality of life using Markov based clinical nomograms[J]. Gastroenterology, 2010, 138(2): 531-540. DOI: 10.1053/j. gastro.2009.10.001.
[78]	KEANE MG, AFGHANI E. A review of the diagnosis and management of premalignant pancreatic cystic lesions[J]. J Clin Med, 2021, 10(6) : 1284. DOI: 10.3390/jcm10061284.
[79]	BAR MASHIAH A, ARONSON A, NAPARST M, et al. Elevated hemoglobin A1c is associated with the presence of pancreatic cysts in a high risk pancreatic surveillance program[J]. BMC Gastroenterol, 2020, 20(1): 161. DOI: 10.1186/s 12876020-01308-w.
[80]	BOURSI B, FINKELMAN B, GIANTONIO BJ, et al. A clinical prediction model to assess risk for pancreatic cancer among patients with new onset diabetes[J]. Gastroenterology, 2017, 152(4): 840-850.e3. DOI: 10.1053/j.gastro.2016.11.046.
[81]	HUANG BZ, PANDOL SJ, JEON CY, et al. New onset diabetes, longitudinal trends in metabolic markers, and risk of pancreatic cancer in a heterogeneous population[J]. Clin Gastroenterol Hepatol, 2020, 18(8): 1812-1821.e7. DOI: 10.1016/j.cgh.2019.11.043.
[82]	SADR AZODI O, GUDBJ RNSDOTTIR S, LJUNG R. Pattern of increasing HbA1c levels in patients with diabetes mellitus before clinical detection of pancreatic cancer a population-based nationwide case control study[J]. Acta Oncol, 2015, 54(7): 986-992. DOI: 10.3109/ 0284186X.2015.1006402.
[83]	LIAO WC, TU YK, WU MS, et al. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose response meta-analysis[J]. BMJ, 2015, 350: g7371. DOI: 10.1136/bmj.g7371.
[84]	O′BRIEN DP, SANDANAYAKE NS, JENKINSON C, et al. Serum CA199 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection[J]. Clin Cancer Res, 2015, 21(3): 622-631. DOI: 10.1158/10780432.CCR-14-0365.
[85]	YANG J, XU R, WANG C, et al. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review[J]. Cancer Commun (Lond), 2021, 41(12): 1257-1274. DOI: 10.1002/cac2.12204.
[86]	KAUHANEN SP, KOMAR G, SEPPNEN MP, et al. A prospective diagnostic accuracy study of 18F fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer[J]. Ann Surg, 2009, 250(6): 957-963. DOI: 10.1097/SLA. 0b013e3181b 2fafa.
[87]	KANG HJ, LEE JM, JOO I, et al. Assessment of malignant potential in intraductal papillary mucinous neoplasms of the pancreas: Comparison between multidetector CT and MR imaging with MR cholangiopancreatography[J]. Radiology, 2016, 279(1): 128-139. DOI: 10.1148/radiol.2015150217.
[88]	Group of Pancreas Surgery, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the diagnosis and treatment of pancreatic cancer in China(2021)[J]. Chin J Surg, 2021, 59(7): 561-577. DOI: 10.3760/cma.j.cn112139-20210416-00171. 中华医学会外科学分会胰腺外科学组. 中国胰腺癌诊治指南(2021)[J]. 中华外科杂志, 2021, 59(7): 561-577. DOI: 10.3760/cma.j.cn1121392021041600171.
[89]	UDARE A, AGARWAL M, ALABOUSI M, et al. Diagnostic accuracy of MRI for differentiation of benign and malignant pancreatic cystic lesions compared to CT and endoscopic ultrasound: Systematic review and meta-analysis[J]. J Magn Reson Imaging, 2021, 54(4): 1126-1137. DOI: 10.1002/jmri.27606.
[90]	KHASHAB MA, YONG E, LENNON AM, et al. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors[J]. Gastrointest Endosc, 2011, 73(4): 691-696. DOI: 10.1016/j.gie.2010.08.030.
[91]	SUN XZ, SUN SY. Role of EUS in screening of pancreatic cancer[J]. Chin J Pract Intern Med, 2021, 41(5): 358-361. DOI: 10.19538/j. nk2021050102. 孙心竹, 孙思予. 超声内镜在胰腺癌筛查中的作用[J]. 中国实用内科杂志, 2021, 41(5): 358-361. DOI: 10.19538/j. nk2021050102.
[92]	CANTO MI, HRUBAN RH, FISHMAN EK, et al. Frequent detection of pancreatic lesions in asymptomatic high risk individuals[J]. Gastroenterology, 2012, 142(4): 796-804; quiz e14-15. DOI: 10.1053/j.gastro.2012.01.005.
[93]	HARINCK F, KONINGS IC, KLUIJT I, et al. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high risk individuals[J]. Gut, 2016, 65(9): 1505-1513. DOI: 10.1136/gutjnl-2014-308008.
[94]	SHI YJ, LI XT, ZHANG XY, et al. Non gaussian models of 3 Tesla diffusion weighted MRI for the differentiation of pancreatic ductal adenocarcinomas from neuroendocrine tumors and solid pseudopapillary neoplasms[J]. Magn Reson Imaging, 2021, 83: 68-76. DOI: 10.1016/j.mri.2021.07.006.
[95]	GUO T, XU T, ZHANG S, et al. The role of EUS in diagnosing focal autoimmune pancreatitis and differentiating it from pancreatic cancer[J]. Endosc Ultrasound, 2021, 10(4): 280-287. DOI: 10.4103/EUS-D-20-00212.
[96]	OVERBEEK KA, LEVINK I, KOOPMANN B, et al. Long term yield of pancreatic cancer surveillance in high risk individuals[J]. Gut, 2021, DOI: 10.1136/gutjnl-2020-323611. [Online ahead of print]
[97]	KOGEKAR N, DIAZ KE, WEINBERG AD, et al. Surveillance of high risk individuals for pancreatic cancer with EUS and MRI: A meta analysis[J]. Pancreatology, 2020, 20(8): 1739-1746. DOI: 10.1016/j.pan.2020.10.025.
[98]	WANI S, HAN S, SIMON V, et al. Setting minimum standards for training in EUS and ERCP: Results from a prospective multicenter study evaluating learning curves and competence among advanced endoscopy trainees[J]. Gastrointest Endosc, 2019, 89(6): 1160-1168.e9. DOI: 10.1016/j.gie.2019.01.030.
[99]	CHO SH, SONG TJ, SEO DW, et al. Efficacy and safety of EUS guided through the needle microforceps biopsy sampling in categorizing the type of pancreatic cystic lesions[J]. Gastrointest Endosc, 2022, 95(2): 299-309. DOI: 10.1016/j. gie.2021.09.035.
[100]	Cho IR, Jeong SH, Kang H, et al. Comparison of contrast-enhanced versus conventional EUS-guided FNA/fine-needle biopsy in diagnosis of solid pancreatic lesions: A randomized controlled trial[J]. Gastrointest Endosc, 2021, 94(2): 303-310. DOI: 10.1016/j.gie.2021.01.018.
[101]	Expert Committee on Endoscopic Ultrasonography, Chinese Medical Doctor Association. Chinese guideline for the clinical practice of endoscopic ultrasound-guided fine-needle aspiration/biopsy(2021, Shanghai)[J]. Chin J Dig Endosc, 2021, 38(5): 337-360. DOI: 10.3760/cma. j. cn3214632021030200143. 中国医师协会超声内镜专家委员会. 中国内镜超声引导下细针穿刺抽吸/活检术应用指南(2021, 上海)[J]. 中华消化内镜杂志, 2021, 38(5): 337-360. DOI: 10.3760/cma. j. cn321463-2021030200143.
[102]	YOON WJ, DAGLILAR ES, MINO-KENUDSON M, et al. Characterization of epithelial subtypes of intraductal papillary mucinous neoplasm of the pancreas with endoscopic ultrasound and cyst fluid analysis[J]. Endoscopy, 2014, 46(12): 1071-1077. DOI: 10.1055/s-0034-1377629.
[103]	MORIS M, RAIMONDO M, WOODWARD TA, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration cytology, carcinoembryonic antigen, and amylase in intraductal papillary mucinous neoplasm[J]. Pancreas, 2016, 45(6): 870-875. DOI: 10.1097/MPA.0000000000000559.
[104]	MCCARTY TR, PALETI S, RUSTAGI T. Molecular analysis of EUS acquired pancreatic cyst fluid for KRAS and GNAS mutations for diagnosis of intraductal papillary mucinous neoplasia and mucinous cystic lesions: A systematic review and meta analysis[J]. Gastrointest Endosc, 2021, 93(5): 1019-1033.e5. DOI: 10.1016/j.gie.2020.12.014.
[105]	HANADA K, MINAMI T, SHIMIZU A, et al. Roles of ERCP in the early diagnosis of pancreatic cancer[J]. Diagnostics (Basel), 2019, 9(1). DOI: 10.3390/diagnostics9010030.
[106]	MIKATA R, ISHIHARA T, TADA M, et al. Clinical usefulness of repeated pancreatic juice cytology via endoscopic naso pancreatic drainage tube in patients with pancreatic cancer[J]. J Gastroenterol, 2013, 48(7): 866-873. DOI: 10.1007/ s005350120684y.
[107]	IIBOSHI T, HANADA K, FUKUDA T, et al. Value of cytodiagnosis using endoscopic nasopancreatic drainage for early diagnosis of pancreatic cancer: Establishing a new method for the early detection of pancreatic carcinoma in situ[J]. Pancreas, 2012, 41(4): 523-529. DOI: 10.1097/MPA.0b013e31823c0b05.
[108]	OKUSAKA T, NAKAMURA M, YOSHIDA M, et al. Clinical practice guidelines for pancreatic cancer 2019 from the japan pancreas society: A synopsis[J]. Pancreas, 2020, 49(3): 326-335. DOI: 10.1097/MPA.0000000000001513.
[109]	VILAS BOAS F, MACEDO G. Pancreatic cystic lesions: New endoscopic trends in diagnosis[J]. J Clin Gastroenterol, 2018, 52(1): 13-19. DOI: 10.1097/MCG.0000000000000945.
[110]	NAGAYOSHI Y, ASO T, OHTSUKA T, et al. Peroral pancreatoscopy using the SpyGlass system for the assessment of intraductal papillary mucinous neoplasm of the pancreas[J]. J Hepatobiliary Pancreat Sci, 2014, 21(6): 410-417. DOI: 10.1002/jhbp.44.
[111]	PITMAN MB, CENTENO BA, ALI SZ, et al. Standardized terminology and nomenclature for pancreatobiliary cytology: The Papanicolaou Society of Cytopathology Guidelines[J]. Cytojournal, 2014, 11(Suppl 1): 3. DOI: 10.4103/1742-6413.133343.
[112]	KIM TH, SONG TJ, LEE SO, et al. Main duct and mixed type intraductal papillary mucinous neoplasms without enhancing mural nodules: Duct diameter of less than 10 mm and segmental dilatation of main pancreatic duct are findings support surveillance rather than immediate surgery[J]. Pancreatology, 2019, 19(8): 1054-1060. DOI: 10.1016/j. pan.2019.09.010.
[113]	DBOUK M, BREWER GUTIERREZ OI, LENNON AM, et al. Guidelines on management of pancreatic cysts detected in high-risk individuals: An evaluation of the 2017 Fukuoka guidelines and the 2020 International Cancer of the Pancreas Screening (CAPS) consortium statements[J]. Pancreatology, 2021, 21(3): 613-621. DOI: 10.1016/j.pan.2021.01.017.
[114]	LUU HN, PARAGOMI P, WANG R, et al. Composite score of healthy lifestyle factors and the risk of pancreatic cancer in a prospective cohort study[J]. Cancer Prev Res (Phila), 2022, 15(1): 29-36. DOI: 10.1158/1940-6207.CAPR-21-0205.
[115]	KOYANAGI YN, ITO H, MATSUO K, et al. Smoking and pancreatic cancer incidence: a pooled analysis of 10 population-based cohort studies in Japan[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(8): 1370-1378. DOI: 10.1158/10559965.
[116]	BOSETTI C, LUCENTEFORTE E, SILVERMAN DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case Control Consortium (Panc4) [J]. Ann Oncol, 2012, 23(7): 1880-1888. DOI: 10.1093/ annonc/mdr541.
[117]	ARSLAN AA, HELZLSOUER KJ, KOOPERBERG C, et al. Anthropometric measures, body mass index, and pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan) [J]. Arch Intern Med, 2010, 170(9): 791-802. DOI: 10.1001/archinternmed.2010.63.
[118]	MAISONNEUVE P, LOWENFELS AB. Risk factors for pancreatic cancer: A summary review of meta-analytical studies[J]. Int J Epidemiol, 2015, 44(1): 186-198. DOI: 10.1093/ije/dyu240.
[119]	PERRY LM, BATENI SB, BOLD RJ, et al. Is improved survival in early stage pancreatic cancer worth the extra cost at high-volume centers? [J]. J Am Coll Surg, 2021, 233(1): 90-98. DOI: 10.1016/j.jamcollsurg.2021.02.014.
[120]	KLEIN AP, WOLPIN BM, RISCH HA, et al. Genome wide meta analysis identifies five new susceptibility loci for pancreatic cancer[J]. Nat Commun, 2018, 9(1): 556. DOI: 10.1038/s41467018029425.
[121]	MATSUBAYASHI H, TAKAORI K, MORIZANE C, et al. Familial pancreatic cancer and surveillance of high risk individuals[J]. Gut Liver, 2019, 13(5): 498-505. DOI: 10.5009/gnl18449.
[122]	KUWAHARA T, HARA K, MIZUNO N, et al. Usefulness of deep learning analysis for the diagnosis of malignancy in intraductal papillary mucinous neoplasms of the pancreas[J]. Clin Transl Gastroenterol, 2019, 10(5): 1-8. DOI: 10.14309/ ctg.0000000000000045.
[123]	CORRAL JE, DAS A, BRUNO MJ, et al. Cost effectiveness of pancreatic cancer surveillance in high-risk individuals: an economic analysis[J]. Pancreas, 2019, 48(4): 526-536. DOI: 10.1097/MPA.0000000000001268.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (1365) PDF downloads(305)

Chinese consensus on the early screening and surveillance for pancreatic cancer in high-risk individuals (2021, Nanjing)

DOI: 10.3969/j.issn.1001-5256.2022.05.008

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Chinese consensus on the early screening and surveillance for pancreatic cancer in high-risk individuals (2021, Nanjing)

DOI: 10.3969/j.issn.1001-5256.2022.05.008

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content